MannKind Corporation met with the FDA regarding its plan file for approval.
5 reports, 3 independent
Updated Jul 24
Gone quiet
- Reports
- 5
- Developments
- 3
- Repetition
- 40%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MannKind Corporation met with the FDA regarding its plan file for approval.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.Update on drug trial decisions and royalty streams involving FDA review.1 source
MannKind met FDA plan file for approval for its inhaled insulin product.1 source
- Dr. Haller appointed to chair the Phase 3 study for MannKind Corporation.
Keep exploring
The entities involved
- FDA
-
MannKind Corporation
biopharmaceutical company
Related events
- FDA approval enables commercial opportunity involving CBRE Group.
- Amylyx Pharmaceuticals is seeking FDA approval for a new drug treatment.
- A product was launched in the U.S. market following FDA involvement.
- Biocon's subsidiary received FDA approval for a drug in the United States on August 18, 2026.
- Jazz Pharmaceuticals received FDA approval for a drug following positive clinical trial results.
Coverage
Newest first; wire copies grouped- finanznachrichten.de
- insidermonkey.com
- Insider MonkeyRBC Capital Lowered the PT on MannKind Corporation (MNKD), Kept a Buy Rating MannKind Corporation (NASDAQ:MNKD) is one of the High Growth Penny Stocks That Are Profitable in 2025. On July 23, RBC Cap
- Unknown outlet